We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
- Authors
Krop, Ian E; Beeram, Muralidhar; Modi, Shanu; Jones, Suzanne F; Holden, Scott N; Yu, Wei; Girish, Sandhya; Tibbitts, Jay; Yi, Joo-Hee; Sliwkowski, Mark X; Jacobson, Fred; Lutzker, Stuart G; Burris, Howard A
- Abstract
Trastuzumab-DM1 (T-DM1) is an antibody-drug conjugate that uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive cells. This first-in-human study of T-DM1 evaluated safety, pharmacokinetics, and preliminary activity of T-DM1 in patients with advanced HER2-positive breast cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 16, p2698
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.26.2071